Partial breast irradiation as sole therapy for low risk breast carcinoma: Early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase II study

Belkacémi, Yazid; Chauvet, Marie‐Pierre; Giard, S.; Villette, S.; Lacornerie, T.; Bonodeau, F.; Baranzelli, Marie-Christine; Bonneterre, Jacques; Lartigau, É.

doi:10.1016/j.radonc.2008.06.004

Cited by 62 publications

(29 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[81][82][83][84][85][86][87] In Europe, several feasibility studies have been initiated to investigate the practicability and safety of the system. [88][89][90][91][92] Most of these trials have been designed to test the device as the sole method for APBI and for the delivery of a boost dose in combination with WBI.…”

Section: Other Multicatheter Apbi Experiencesmentioning

confidence: 99%

“…[81][82][83][84][85][86][87][88][89][90][91][92] To date, only two groups have reported their 81 Criteria for entry into the study were unifocal invasive ductal carcinoma, tumor size 2 cm or less, age 45 years or more, absence of EIC, cavity size 3 cm or more, negative axillary nodes, and clear fi nal surgical margins. A minimum balloon-to-skin surface distance of 5 mm was required.…”

Section: Other Multicatheter Apbi Experiencesmentioning

confidence: 99%

See 1 more Smart Citation

Current status and perspectives of brachytherapy for breast cancer

Polgár

Major

2009

Int J Clin Oncol

View full text Add to dashboard Cite

Before the era of breast-conserving therapy, brachytherapy implants were used to treat large inoperable breast tumors. In later years, interstitial brachytherapy with rigid needles or multiple flexible catheters has been used to deliver an additional (boost) dose to the tumor bed after breast-conserving surgery and whole-breast irradiation. Reexcision followed by reirradiation using interstitial breast implants has also been implemented as an alternative to mastectomy to treat ipsilateral breast local recurrence after previous breast-conserving therapy. In the past two decades, the new concept of accelerated partial breast irradiation opened a new perspective for breast brachytherapy. The first technique utilized in early accelerated partial breast irradiation studies was multicatheter interstitial brachytherapy. Beyond classical interstitial brachytherapy, recently, new intracavitary applicators have been developed in the United States to decrease the existing barriers against the widespread use of multicatheter brachytherapy. Furthermore, interstitial low-dose-rate seed implants have also been implemented as an alternative for stepping-source multicatheter brachytherapy. In this article, we give an overview of the past achievements, current status, and future perspectives of breast brachytherapy.

show abstract

Section: Other Multicatheter Apbi Experiencesmentioning

confidence: 99%

Section: Other Multicatheter Apbi Experiencesmentioning

confidence: 99%

Current status and perspectives of brachytherapy for breast cancer

Polgár

Major

2009

Int J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Currently, there are only a few of published studies comparing QoL between APBI and WBI in China [17][18][19]. The purpose of this study was to compare the QoL of EBC patients treated with APBI versus WBI after breast-conserving therapy using retrospective analysis.…”

Section: Introductionmentioning

confidence: 99%

A comparison of quality of life of early breast cancer patients treated with accelerated partial breast irradiation versus whole breast irradiation in China

Tong

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

To compare quality of life (QoL) of early breast cancer patients treated with either accelerated partial breast irradiation (APBI) or whole breast irradiation (WBI) after breast-conserving therapy in China. The functional assessment of chronic illness therapy-Breast, traditional Chinese version 4 (FACT-B) instruments were given to 84 women (31 APBI and 53 WBI) who attended the radiotherapy clinic between July 2006 and May 2009 at Cancer Center of Sun Yat-sen University. Baseline characteristics and Karnofsky performance status scores were not different between the two groups. The median follow-up period in the APBI group was 29 versus 34 months in the WBI group. The APBI group scores in the physical domain, functional domain, social domain, and breast-specific concerns of FACT-B were 23.01 ± 3.91, 17.97 ± 4.99, 20.87 ± 4.80, and 22.55 ± 5.45, respectively, and were not significantly different from those of the WBI group (22.80 ± 3.50, 17.50 ± 4.40, 20.13 ± 5.31, 23.81 ± 4.65, respectively, P = 0.987, P = 0.476, P = 0.442, P = 0.330, respectively). However, the scores of the APBI group with respect to the emotional domains were lower compared to those of the WBI group (16.84 ± 3.86 vs. 19.47 ± 3.45, respectively, P = 0.002). Compared with women who underwent WBI, women treated with APBI were shown to have no significantly better QoL outcome, and yet had worse emotional response to their treatment.

show abstract

“…A phase II study from Europe enrolled 43 patients 2003 to 2005 with T1N0 breast cancer [86]. The median age was 72 years.…”

Section: Balloon Cathetermentioning

confidence: 99%

Assessment of Accelerated Partial Breast Irradiation as Monotherapy Following Breast Conserving Surgery in the Treatment of Favorable Risk Breast Cancer

Sharma¹,

Ansari²,

Churchill³

et al. 2018

ABCR

View full text Add to dashboard Cite

show abstract

Partial breast irradiation as sole therapy for low risk breast carcinoma: Early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase II study

Cited by 62 publications

References 50 publications

Current status and perspectives of brachytherapy for breast cancer

Current status and perspectives of brachytherapy for breast cancer

A comparison of quality of life of early breast cancer patients treated with accelerated partial breast irradiation versus whole breast irradiation in China

Assessment of Accelerated Partial Breast Irradiation as Monotherapy Following Breast Conserving Surgery in the Treatment of Favorable Risk Breast Cancer

Contact Info

Product

Resources

About